# Evaluating Effectiveness and Long Term Safety of Damoctocog Alfa Pegol in Patients, Who Have Been Diagnosed With Hemophilia A

> **NCT03932201** · — · ACTIVE_NOT_RECRUITING · sponsor: **Bayer** · enrollment: 371 (actual)

## Conditions studied

- Hemophilia A

## Interventions

- **DRUG:** Damoctocog alfa pegol (Jivi, Bay94-9027)

## Key facts

- **NCT ID:** NCT03932201
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-10-21
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-03-31
- **Target enrollment:** 371 (ACTUAL)
- **Last updated:** 2026-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03932201

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03932201, "Evaluating Effectiveness and Long Term Safety of Damoctocog Alfa Pegol in Patients, Who Have Been Diagnosed With Hemophilia A". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03932201. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*